Results from Phase I Study of CB-839 in Combination with Everolimus or Cabozantinib in Patients with Renal Cell Carcinoma to be ...
-Overall response rate of 40% and 100% disease control rate in advanced clear cell renal cell carcinoma patients treated with CB-839 plus Cabozantinib -Randomized placebo controlled CANTATA Phase 2 trial of CB-839 in combination with Cabozantinib to begin …